Artelo Biosciences
ARTL
7 hedge funds and large institutions have $75.8K invested in Artelo Biosciences in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
107% more capital invested
Capital invested by funds: $36.6K → $75.8K (+$39.2K)
40% more funds holding
Funds holding: 5 → 7 (+2)
0.09% more ownership
Funds ownership: 0.06% → 0.15% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$25.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$100 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$583 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $23.4K | +$10.5K | +523 | +54% |
|
|
2
Citadel Advisors
Miami,
Florida
| $19.9K | +$25.3K | +1,261 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $17.8K | +$22.8K | +1,133 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $11.2K | -$583 | -29 | -4% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.42K | +$100 | +5 | +2% |
|
|
6
Bank of America
Charlotte,
North Carolina
| $24 | +$20 | +1 | +100% |
|
7
Morgan Stanley
New York
| $18 | – | – | – |
|
|
RIL
8
Rothschild Investment LLC
Chicago,
Illinois
| $7 | – | – | – |
|
ARTL Hedge Fund Activity: Q1 2025 in Review
7 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2025, worth a combined $75.8K — up 107% from $36.6K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ARTL positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $25.3K. The largest seller was UBS Group, cutting an estimated $583.
- 7 institutional investors held Artelo Biosciences (ARTL) as of Q1 2025, up from 5 in Q4 2024.
- Funds reported $75.8K of Artelo Biosciences stock for Q1 2025, up 107% quarter-over-quarter.
- 2 funds opened new Artelo Biosciences positions in Q1 2025 and 0 closed out, a net change of +2 holders.
- The largest Artelo Biosciences buyer in Q1 2025 was Citadel Advisors, an estimated $25.3K added.
- The largest Artelo Biosciences seller in Q1 2025 was UBS Group, an estimated $583 sold.
Based on aggregated 13F filings for Q1 2025.